US Dural Arteriovenous Fistulas Treatment Market

ID: MRFR/Pharma/16782-HCR
100 Pages
Vikita Thakur
Last Updated: April 06, 2026
United States Dural Arteriovenous Fistulas Treatment Market Research Report: Size, Share, Trend Analysis - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Pharmaceutical, BY Treatment Type (USD Million)
      1. 4.1.1 Endovascular Intervention
      2. 4.1.2 Surgery
      3. 4.1.3 Radiation Therapy
      4. 4.1.4 Medication
    2. 4.2 Pharmaceutical, BY Procedure Type (USD Million)
      1. 4.2.1 Transarterial Embolization
      2. 4.2.2 Surgical Excision
      3. 4.2.3 Stereotactic Radiosurgery
    3. 4.3 Pharmaceutical, BY Diagnosis Type (USD Million)
      1. 4.3.1 Magnetic Resonance Imaging
      2. 4.3.2 Computed Tomography
      3. 4.3.3 Digital Subtraction Angiography
    4. 4.4 Pharmaceutical, BY Patient Type (USD Million)
      1. 4.4.1 Adult
      2. 4.4.2 Pediatric
    5. 4.5 Pharmaceutical, BY Healthcare Setting (USD Million)
      1. 4.5.1 Hospitals
      2. 4.5.2 Ambulatory Surgical Centers
      3. 4.5.3 Specialized Clinics
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Pharmaceutical
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Medtronic (IE)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Stryker (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Johnson & Johnson (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Boston Scientific (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Terumo (JP)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 B. Braun (DE)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Abbott (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Penumbra (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TREATMENT TYPE
    3. 6.3 US MARKET ANALYSIS BY PROCEDURE TYPE
    4. 6.4 US MARKET ANALYSIS BY DIAGNOSIS TYPE
    5. 6.5 US MARKET ANALYSIS BY PATIENT TYPE
    6. 6.6 US MARKET ANALYSIS BY HEALTHCARE SETTING
    7. 6.7 KEY BUYING CRITERIA OF PHARMACEUTICAL
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF PHARMACEUTICAL
    10. 6.10 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
    12. 6.12 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
    13. 6.13 PHARMACEUTICAL, BY TREATMENT TYPE, 2024 (% SHARE)
    14. 6.14 PHARMACEUTICAL, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    15. 6.15 PHARMACEUTICAL, BY PROCEDURE TYPE, 2024 (% SHARE)
    16. 6.16 PHARMACEUTICAL, BY PROCEDURE TYPE, 2024 TO 2035 (USD Million)
    17. 6.17 PHARMACEUTICAL, BY DIAGNOSIS TYPE, 2024 (% SHARE)
    18. 6.18 PHARMACEUTICAL, BY DIAGNOSIS TYPE, 2024 TO 2035 (USD Million)
    19. 6.19 PHARMACEUTICAL, BY PATIENT TYPE, 2024 (% SHARE)
    20. 6.20 PHARMACEUTICAL, BY PATIENT TYPE, 2024 TO 2035 (USD Million)
    21. 6.21 PHARMACEUTICAL, BY HEALTHCARE SETTING, 2024 (% SHARE)
    22. 6.22 PHARMACEUTICAL, BY HEALTHCARE SETTING, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY PROCEDURE TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      4. 7.2.4 BY PATIENT TYPE, 2025-2035 (USD Million)
      5. 7.2.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US US Dural Arteriovenous Fistulas Treatment Market Segmentation

US Dural Arteriovenous Fistulas Treatment Market By Treatment Type (USD Million, 2025-2035)

  • Endovascular Intervention
  • Surgery
  • Radiation Therapy
  • Medication

US Dural Arteriovenous Fistulas Treatment Market By Procedure Type (USD Million, 2025-2035)

  • Transarterial Embolization
  • Surgical Excision
  • Stereotactic Radiosurgery

US Dural Arteriovenous Fistulas Treatment Market By Diagnosis Type (USD Million, 2025-2035)

  • Magnetic Resonance Imaging
  • Computed Tomography
  • Digital Subtraction Angiography

US Dural Arteriovenous Fistulas Treatment Market By Patient Type (USD Million, 2025-2035)

  • Adult
  • Pediatric

US Dural Arteriovenous Fistulas Treatment Market By Healthcare Setting (USD Million, 2025-2035)

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialized Clinics

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035